BlueCrest Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

BlueCrest Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-46,864	Closed	-$1.6M	–	230
2023 Q2	$1.6M	Buy	+46,864	New	+$1.47M	0.05%	120
2021 Q3	–	Sell	-14,720	Closed	-$1.36M	–	372
2021 Q2	$1.36M	Buy	+14,720	New	+$1.25M	0.03%	353
2021 Q1	–	Sell	-3,479	Closed	-$324K	–	631
2020 Q4	$324K	Sell	3,479 -8,971	-72%	-$715K	0.01%	341
2020 Q3	$793K	Buy	+12,450	New	+$730K	0.03%	214

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

BlueCrest Capital Management's ARKG Position: Q3 2023 in Review

BlueCrest Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2023, closing a stake of 46,864 shares — an estimated $1.6M sold.

BlueCrest Capital Management first reported a position in ARKG in Q3 2020 and held it in 4 quarters. The position peaked at $1.6M in Q2 2023. 286 funds tracked by Wall St. Rank hold ARKG as of Q3 2023.

BlueCrest Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q3 2023 after selling out during the quarter.
BlueCrest Capital Management sold 46,864 ARK Genomic Revolution ETF shares in Q3 2023, an estimated $1.6M.
BlueCrest Capital Management first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 4 quarters.
BlueCrest Capital Management's ARK Genomic Revolution ETF position peaked at $1.6M in Q2 2023.
286 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2023.

Based on BlueCrest Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.